Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Prothena (PRTA – Research Report) today and set a price target of $94.00. The company’s shares closed yesterday at $39.62.
Rahimi covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Structure Therapeutics, Inc. Sponsored ADR, and Prothena. According to TipRanks, Rahimi has an average return of 9.2% and a 39.36% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Prothena with a $75.88 average price target, a 91.52% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $87.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $79.65 and a one-year low of $28.51. Currently, Prothena has an average volume of 907.8K.
Based on the recent corporate insider activity of 92 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRTA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prothena (PRTA) Company Description:
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Read More on PRTA:
- Prothena remains on track with partnered programs, provides updates
- The biotech stocks to own in 2024, according to Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank
- Prothena initiated with bullish view at Deutsche Bank, here’s why
